Evidence map›Paper›PMID 34956198›Full record

ArticleFrontiers in immunology2021

Pro-Inflammatory Signature in Decidua of Recurrent Pregnancy Loss Regardless of Embryonic Chromosomal Abnormalities.

Zaigui Wu, Miaomiao Wang, Guanmian Liang, Pengzhen Jin, Peng Wang, Yuqing Xu, Yeqing Qian, Xiuxiu Jiang, Junbin Qian, Minyue Dong

Abstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zaigui WuWomen's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Miaomiao WangWomen's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Guanmian LiangCancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
Pengzhen JinWomen's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Peng WangWomen's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yuqing XuWomen's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yeqing QianWomen's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiuxiu JiangWomen's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Junbin QianWomen's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Minyue DongWomen's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recurrent pregnancy loss (RPL), especially the unexplained RPL, is associated with the disruption of maternal immune tolerance. However, little is known about the immune status at the decidua of RPL with embryonic chromosomal aberrations. Herein, mass cytometry (CyTOF) was used to interrogate the immune atlas at the decidua which was obtained from 15 RPL women-six with normal chromosome and nine with chromosomal aberrations-and five controls. The total frequency of CCR2

Indexed as

Abortion, HabitualAdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChromosome AberrationsDeciduaEmbryo, MammalianFemaleHumansInflammationKiller Cells, NaturalMacrophagesPregnancyYoung AdultCyTOFdeciduaembryonic chromosomal aberrationsmaternal immune tolerancerecurrent pregnancy loss

Identifiers

PMID34956198
PMCPMC8694032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.